Allergy Therapeutics PLC (AIM:AGY, FRA:HHU)’s study evaluating biomarkers from peanut-allergic patients’ blood samples using its VLP Peanut vaccine candidate confirm its hypoallergic potential and should strengthen the company’s Phase I study IND application to the FDA in late 2021, says finnCap.
While the broker’s target price remains 45p, it adds there is substantial potential upside as VLP Peanut progresses through the clinic.
Together with a recently completed multiple-dose toxicology study, Allergy believes it has the necessary information as to the starting dose as well as dose escalations planned in its proposed Phase I study, scheduled to start in the first half of 2022.
Although yet to enter the clinic, these data de-risk the development programme, says finnCap.
"The opportunity and potential value for a novel, efficacious vaccine remains high; perhaps best illustrated by the $2.6bn acquisition of Aimmune by Nestle in 2020."